BackClarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Receivables

Clarus Therapeutics Holdings's receivables is $8.7M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$8.71M
39.75% YoYΔ $2.48M vs prior year quarter

Peer trimmed avg / median

Loading

Clarus Therapeutics Holdings Receivables History

Loading

Clarus Therapeutics Holdings vs. peers: Receivables Comparison

Loading

Clarus Therapeutics Holdings Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Clarus Therapeutics Holdings (CRXT) FAQ

As of the most recent data (June 2022), CRXT shows a receivables of $8.7M. That compares with $6.2M in the prior-year period — up 39.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CRXT's receivables is now $8.7M (was $6.2M) — a 39.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Clarus Therapeutics Holdings is outperforming or lagging.

Tracking CRXT's receivables over time shows whether Clarus Therapeutics Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $8.7M That compares with $6.2M in the prior-year period — up 39.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Clarus Therapeutics Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $8.7M) with ownership activity and broader fundamentals.